Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$109.46 USD
+2.03 (1.89%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $109.54 +0.08 (0.07%) 6:30 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
JAZZ 109.46 +2.03(1.89%)
Will JAZZ be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JAZZ
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
Other News for JAZZ
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community
Jazz Pharmaceuticals (JAZZ) Gets a Buy from Barclays
Jazz Pharmaceuticals: Cheap But Complicated
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024